EuroQol 5D

1. Abstract

The EuroQol 5-Dimension (EQ-5D, specifically the foundational three-level version, EQ-5D-3L) is a standardized, preference-based instrument developed by the international EuroQol Group to measure generic health-related quality of life (HRQoL). Designed for clinical assessment, health population surveys, and economic evaluations such as cost-utility analysis, the questionnaire evaluates health across five distinct core dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension is appraised via a three-level ordinal scale denoting no problems, some or moderate problems, and severe or extreme problems, defining a total of 243 theoretically unique health states. The descriptive system is complemented by the EuroQol Visual Analogue Scale (EQ VAS), a vertical, continuous scale ranging from 0 (“The worst health you can imagine”) to 100 (“The best health you can imagine”), which captures direct self-rated health status from the respondent’s internal perspective.

Psychometrically, the EQ-5D demonstrates strong measurement properties across general and clinical populations worldwide. Construct and convergent validity are evidenced by substantial correlations with established multi-item measures, including the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and disease-specific functional metrics, yielding correlations typically ranging between r = 0.50 and r = 0.75. Known-groups validity consistently demonstrates significant differentiations between cohorts stratified by chronic disease severity, acute clinical staging, and age. Reliability evaluations demonstrate acceptable to high test-retest stability, with weighted Cohen’s kappa (κ) values across individual dimensions spanning 0.65 to 0.85 and intraclass correlation coefficients (ICC) for the utility index and EQ VAS typically exceeding 0.78 to 0.90 in stable clinical cohorts. Health state profiles can be translated into preference-weighted health utilities anchored on a scale where 1.0 represents full health and 0.0 represents a state equivalent to death (with negative values denoting states considered worse than dead) using country-specific valuation tariffs derived via the time trade-off (TTO) methodology. The instrument serves as a cornerstone of international health technology assessment (HTA), pharmacological comparative effectiveness research, and epidemiological monitoring.

2. Keywords

EuroQol 5D, EQ-5D-3L, Health-Related Quality of Life, Health Technology Assessment, Quality-Adjusted Life Years, Psychometrics, Visual Analogue Scale, Health Utility Index, Time Trade-Off, Construct Validity

3. Authors

The EuroQol 5D instrument was formulated, tested, and validated by the EuroQol Group, an international, multidisciplinary network of psychometricians, health economists, epidemiologists, and clinical researchers founded in 1987. Initial development was spearheaded by prominent foundational members, including:

• Alan Williams – Department of Economics, University of York, Heslington, York, United Kingdom.
• Rachel Rosser – Department of Psychiatry, University College London Medical School, London, United Kingdom.
• Frank de Charro – Department of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands.
• Paul Kind – Centre for Health Economics, University of York, Heslington, York, United Kingdom.
• Gudrun Gudex – Centre for Health Economics, University of York, York, United Kingdom.
• Marie-Louise Essink-Bot – Department of Public Health, Erasmus University Rotterdam, Rotterdam, Netherlands.
• Jan Busschbach – Department of Psychiatry, Section of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, Netherlands.

Administrative stewardship, intellectual property management, translation harmonization, and scientific dissemination are overseen by the EuroQol Research Foundation, located at Marten Meesweg 107, 3068 AV Rotterdam, The Netherlands (Website: https://euroqol.org/).

4. Purpose

The primary purpose of the EuroQol 5D is to provide a brief, standardized, and clinically viable self-report instrument to assess generic health status and health-related quality of life (HRQoL). Originally conceived to address the operational and cognitive burdens imposed by lengthy multidimensional health inventories, the EQ-5D was engineered to measure health on a universal metric that enables broad comparability across disparate medical conditions, healthcare interventions, and demographic populations. While disease-specific instruments are highly sensitive to narrow clinical changes within an isolated diagnostic category, they lack cross-condition equivalence. The EQ-5D overcomes this structural limitation by measuring fundamental, non-condition-specific functional, somatic, and psychological domains.

Beyond clinical description, a major theoretical rationale for the EQ-5D lies in the field of health economics, specifically in the calculation of Quality-Adjusted Life Years (QALYs). In healthcare resource allocation and health technology assessment (HTA)—such as evaluations conducted by the National Institute for Health and Care Excellence (NICE) in the UK, the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, and the Canadian Agency for Drugs and Technologies in Health (CADTH)—economic models require health status to be converted into single, continuous preference weights known as utility values. The EQ-5D fulfills this requirement by enabling any of its 243 discrete health states to be mapped directly to population-derived valuation tariffs established via rigorous empirical preference elicitation studies.

In clinical practice and clinical trials, the EQ-5D serves as an essential patient-reported outcome measure (PROM) to capture longitudinal changes in physical and mental functioning, track therapeutic recovery or decline, and assess adverse treatment effects. In epidemiological and population health surveys, the instrument allows health authorities to monitor the general health status of national populations, evaluate socioeconomic gradients in disease burden, and evaluate the equitable distribution of healthcare benefits across entire societies.

5. Psychological Construct

The EQ-5D conceptualizes health-related quality of life as a latent, multidimensional construct encompassing functional ability, physical comfort, and psychological well-being. Unlike narrow biomedical metrics centered strictly on objective biomarkers or pathological markers, the construct captured by the EQ-5D reflects the World Health Organization’s (WHO) holistic definition of health as a state of complete physical, mental, and social well-being, rather than merely the absence of disease or infirmity. The instrument systematically evaluates five primary dimensions:

• Mobility: Assesses gross motor functioning, physical independence, and ambulation. This dimension reflects an individual’s biomechanical capacity to navigate their immediate physical environment without insurmountable physical restriction, graded from unhindered mobility to confinement to bed.
• Self-Care: Measures instrumental personal independence, focusing explicitly on primary activities of daily living (ADLs) such as washing and dressing. Psychological autonomy and dignity are tightly linked to this dimension, as deficits denote severe functional dependence on caregivers or assistive equipment.
• Usual Activities: Captures social role functioning, occupation, academic pursuits, family responsibilities, and recreational or leisure activities. It reflects the intersection between somatic capability and environmental demand, quantifying the degree to which health constraints impede role fulfillment within one’s familial, professional, and community contexts.
• Pain / Discomfort: Measures somatic distress, sensory impairment, and physical suffering. The construct integrates both acute somatic sensory experiences (nociception) and the emotional burden, exhaustion, and cognitive disruption associated with persistent or chronic pain conditions.
• Anxiety / Depression: Captures affective and internalizing psychological distress. It measures deviations from baseline emotional equilibrium, spanning common psychological symptoms including pervasive worry, autonomic apprehension, anhedonia, dysphoria, and emotional hopelessness.

In addition to these five discrete categorical dimensions, the psychological construct encompasses global cognitive appraisal of subjective health status, measured via the continuous vertical EQ VAS. This visual analogue component operationalizes the respondent’s holistic, gestalt evaluation of their own health state on any given day, incorporating unmeasured latent elements such as vitality, cognitive clarity, existential outlook, and subjective resilience.

6. Theoretical Framework

The architecture of the EuroQol 5D is grounded in the intersection of psychometric measurement theory, expected utility theory, and the biopsychosocial model of medicine articulated by George Engel. Historically, health assessment was dominated by the clinical-pathological model, which assumed that disease-induced physiological disruptions linearly dictated a patient’s lived experience. The EuroQol Group rejected this unidimensional premise, establishing a conceptual bridge between descriptive functional status profiling and normative decision theory.

Under the behavioral and health economic foundations laid by John von Neumann and Oskar Morgenstern, human decision-making under risk and uncertainty can be modeled through preference functions. Alan Williams and colleagues integrated these axiomatic principles into health state valuation by arguing that different functional health states possess quantifiable values (utilities) relative to the anchors of absolute perfection (full health = 1.0) and death (0.0). To operationalize this theoretical framework, the EuroQol Group paired multi-attribute utility theory (MAUT) with psychometric scale design. Under MAUT, an overall health profile represents a bundle of distinct attributes (the five dimensions), where the composite utility of any health state is an additive or multiplicative function of its attribute levels.

Simultaneously, the scale draws upon classical test theory and cognitive survey methodology. The five dimensions were deliberately selected following extensive cross-national qualitative synthesis, semantic consensus panels, and factor analytic reviews of existing extensive batteries (including the Sickness Impact Profile, the Nottingham Health Profile, and the Rosser Health Status Index). The dimensions represent the minimal irreducible set of core domains necessary to characterize human functional life meaningfully without producing respondent fatigue, cognitive overload, or non-compliance.

7. Validity

The validity of the EuroQol 5D descriptive system and the EQ VAS has been rigorously examined across hundreds of empirical studies spanning diverse clinical specialties, cultural contexts, and language versions.

Construct and Known-Groups Validity

The EQ-5D demonstrates remarkable known-groups validity, showing significant differences (p < .001) in health utility scores and visual analogue scores across cohorts categorized by age, number of comorbid conditions, socioeconomic status, and disease severity stages. For example, in large-scale studies evaluating cardiovascular disorders, EQ-5D utility scores decline monotonically across New York Heart Association (NYHA) functional classes (Class I mean ≈ 0.88; Class II ≈ 0.76; Class III ≈ 0.61; Class IV ≈ 0.38). Similar discriminatory capacity has been documented across rheumatoid arthritis stages (stratified by the American College of Rheumatology functional classification) and chronic obstructive pulmonary disease (stratified by Global Initiative for Chronic Obstructive Lung Disease stages).

Convergent and Discriminant Validity

Convergent validity is confirmed by strong bivariate correlations between corresponding EQ-5D dimensions and established multi-item instruments. The EQ-5D Mobility and Usual Activities dimensions correlate strongly with the Physical Functioning subscale of the SF-36 (Spearman rank correlations typically between r_s = −0.60 and −0.78). The Pain/Discomfort dimension shows pronounced correlation with the SF-36 Bodily Pain domain (r_s = −0.70 to −0.82) and numeric rating scales of pain. The Anxiety/Depression dimension exhibits moderate to strong associations with the Hospital Anxiety and Depression Scale (HADS) and the SF-36 Mental Health subscale (r_s = −0.55 to −0.72).

Discriminant validity is exhibited by low correlations between non-overlapping constructs; for instance, the Mobility dimension generally displays low correlations (r_s < 0.25) with the Mental Health index of the SF-36 or the HADS Depression subscale, confirming that the physical and psychological subcomponents capture distinct, non-collinear facets of functional health.

Predictive and Criterion Validity

The EQ-5D possesses robust predictive validity regarding major clinical and epidemiological outcomes. Baseline EQ-5D index and EQ VAS scores independently predict 1-year and 5-year all-cause mortality, secondary cardiovascular events, institutionalization, and return-to-work trajectories after major surgical interventions, even after adjusting for traditional physiological and demographic risk covariates. Hazard ratios (HR) per 0.1-point decrement in baseline utility score for long-term mortality consistently range from 1.10 to 1.25 across multi-center cohort registries.

8. Reliability

Given that the EQ-5D consists of single-item indicators representing distinct functional domains rather than redundant multiple items per latent factor, traditional internal consistency metrics such as Cronbach’s alpha are technically less applicable and conceptually secondary. Nevertheless, when computed across the five dimensions treated as a unified composite, Cronbach’s alpha values typically fall between 0.68 and 0.82 across diverse patient populations, reflecting acceptable internal coherence without domain redundancy.

Psychometric evaluation of the EQ-5D relies primarily on test-retest reliability and inter-observer consistency. In stable clinical cohorts evaluated over retest intervals spanning 1 to 14 days, the descriptive system displays moderate to high stability:

• Mobility: Weighted Cohen’s kappa (κ_w) values between 0.72 and 0.85.
• Self-Care: κ_w values between 0.68 and 0.83.
• Usual Activities: κ_w values between 0.60 and 0.76.
• Pain / Discomfort: κ_w values between 0.65 and 0.79.
• Anxiety / Depression: κ_w values between 0.58 and 0.74 (lower stability reflecting natural diurnal affective fluctuations).

For the overall derived utility index score, intraclass correlation coefficients (ICC) typically range from 0.80 to 0.93 in stable chronic populations, demonstrating high measurement reproducibility. For the EQ VAS, test-retest ICCs generally range from 0.73 to 0.86, with Bland-Altman limits of agreement confirming that individual differences rarely diverge beyond ±10 to ±15 points on the 100-point scale in the absence of genuine clinical status change.

9. Factor Analysis

Extensive exploratory (EFA) and confirmatory factor analyses (CFA) have evaluated the latent dimensionality of the EQ-5D. Although often combined into a single summary index for economic modeling, structural analyses consistently demonstrate that the five dimensions are best represented by a two-factor oblique model consisting of Physical Health and Mental Health factors.

Factor Loadings and Structural Structure

In classical EFA utilizing principal axis factoring with promax or varimax rotation, the items systematically separate into two robust dimensions:

• Factor 1: Physical Functioning / Somatic Health – Strongly defined by Mobility (loadings typically 0.75–0.88), Self-Care (loadings 0.65–0.82), and Usual Activities (loadings 0.60–0.78). Pain/Discomfort commonly cross-loads moderately (0.35–0.50) onto this factor.
• Factor 2: Mental / Affective Health – Strongly defined by Anxiety/Depression (loadings > 0.80), with moderate secondary contributions from Usual Activities and Pain/Discomfort.

Confirmatory Factor Analysis (CFA) Fit Indices

Confirmatory factor analytic investigations utilizing robust weighted least squares estimation (WLSMV) for categorical indicators demonstrate that a two-factor model provides superior fit relative to a unidimensional specification. Typical model fit indices across large epidemiological datasets (e.g., sample sizes N > 5,000) include:

• Comparative Fit Index (CFI): > 0.985 (indicating excellent fit)
• Tucker-Lewis Index (TLI): > 0.970
• Root Mean Square Error of Approximation (RMSEA): 0.035 to 0.052 (90% CI [0.028, 0.060])
• Standardized Root Mean Square Residual (SRMR): < 0.040

The correlation between the latent Physical and Mental factors typically ranges from r = 0.45 to 0.65, demonstrating substantial shared variance while upholding the psychometric discriminant validity of physical and affective functional impairments.

10. Instrument / Measurement Tool

• Instrument Name: EuroQol 5-Dimension Health Questionnaire, 3-Level Version (EQ-5D-3L).
• Test Type: Generic, standardized, preference-based patient-reported outcome measure (PROM).
• Target Population: Adults (18+ years) and older adults; applicable across general population cohorts and acute or chronic clinical populations.
• Number of Dimensions: 5 (Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/Depression).
• Item Count: 5 descriptive classification items, plus 1 global health rating item (EQ VAS).
• Descriptive Response Scale: 3-level categorical response for each dimension (1 = No problems, 2 = Some/moderate problems, 3 = Severe/extreme problems) plus EQ VAS (0-100 visual analogue scale).
• Descriptive Health State Classification: The responses across the five dimensions are combined into a concise 5-digit health state code (e.g., 11111 indicates no problems on any dimension; 21232 indicates moderate mobility problems, no self-care problems, moderate usual activity problems, extreme pain/discomfort, and moderate anxiety/depression; 33333 represents the worst health state). A total of 3⁵ = 243 theoretically possible health states are defined.
• Scoring and Health Utility Derivation:
  • Health profiles are converted into a single, continuous utility index score using country-specific valuation sets (tariffs) established through empirical valuation studies (primarily time trade-off and visual analogue methods).
  • The theoretical utility scale anchors full health at 1.000 and death at 0.000. States perceived as worse than death receive negative utility values (e.g., down to −0.594 in the UK Dolan tariff).
  • The EQ VAS is recorded directly on a vertical 20-centimeter visual analogue scale calibrated from 0 (‘The worst health you can imagine’) to 100 (‘The best health you can imagine’), representing the patient’s holistic subjective health rating.
• Administration Time: Approximately 2 to 5 minutes, ensuring exceptionally high completion rates (> 95%) and minimal respondent burden.
• Administration Modes: Paper-and-pencil, electronic PRO (ePRO, tablet, smartphone, web), telephone interview, and proxy administration versions.

11. Permissions & Fee and Test Year

The EuroQol instrument was originally published in 1990 by the EuroQol Group. The questionnaire, its descriptive system, the EQ VAS, and all standardized linguistic translations are copyrighted intellectual property owned and managed by the EuroQol Research Foundation.

Licensing and Accessibility:

• Registration Requirement: Any clinical, academic, commercial, or public health use of the EQ-5D requires mandatory registration on the official EuroQol website (euroqol.org) prior to study initiation.
• Academic and Non-Commercial Research: Use of the instrument for non-commercial academic research, investigator-initiated clinical trials, routine clinical care, and general non-funded student projects is typically granted free of charge (fee-exempt) upon registration and formal approval of user terms.
• Commercial and Industry-Sponsored Research: For-profit pharmaceutical trials, contract research organizations (CROs), commercial clinical outcome evaluations, and corporate applications are subject to mandatory licensing agreements and user fees calculated per study, administration mode, and sample size.
• Translations: The EuroQol Foundation provides over 170 certified linguistic translations adhering strictly to standardized forward-backward translation protocols and cross-cultural equivalence validation guidelines. Unofficial translations or unauthorized modifications of the descriptive system and response options are strictly prohibited to maintain worldwide comparability.

12. References

The following foundational and methodological publications document the development, psychometric validation, and valuation methodology of the EQ-5D:

• Brooks, R. (1996). EuroQol: The current state of play. Health Policy, 37(1), 53–72. https://doi.org/10.1016/0168-8510(96)00822-6
• Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108. https://doi.org/10.1097/00005650-199711000-00002
• EuroQol Group. (1990). EuroQol—a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208. https://doi.org/10.1016/0168-8510(90)90421-9
• Herdman, M., Gudex, C., Lloyd, A., Janssen, M. F., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736. https://doi.org/10.1007/s11136-011-9903-x
• Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., Swinburn, P., & Busschbach, J. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research, 22(7), 1717–1727. https://doi.org/10.1007/s11136-012-0322-4
• Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998). Variations in population health status: Results from a United Kingdom national questionnaire survey. BMJ, 316(7133), 736–741. https://doi.org/10.1136/bmj.316.7133.736
• Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol Group. Annals of Medicine, 33(5), 337–343. https://doi.org/10.3109/07853890109002087
• Szende, A., Janssen, B., & Cabases, J. (Eds.). (2014). Self-Reported Population Health: An International Perspective based on EQ-5D. Springer. https://doi.org/10.1007/978-94-007-7596-1
• van Agt, H. M., Essink-Bot, M. L., Krabbe, P. F., & Bonsel, G. J. (1994). Test-retest reliability of health state valuations applied to EuroQol. Social Science & Medicine, 39(11), 1537–1544. https://doi.org/10.1016/0277-9536(94)90005-1
• Williams, A. (1995). The role of the EuroQol instrument in QALY calculations. Centre for Health Economics Discussion Paper 130, University of York.

13. Items of the Scale (Questionnaire)